This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Oncology, Other  • Endocrine Surgery  • Alert me on articles by topic

Michael Trede, MD, HonFRCS, HonFACS
Mannheim, Germany

Arch Surg. 2002;137:773.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The ultimate panegyric that one of my surgical teachers in London would stoop to (if he were really satisfied with something I had done) would be to murmur, "I couldn't have done it better myself!" And that was (with tongue in cheek) my immediate reaction, when reading this editorial. I agree with everything, and I have little to add.

Of the 4 problems that bedevil the treatment of pancreatic carcinoma screening (or at least early diagnosis), accurate staging, postoperative mortality and long-term survival-only staging, and mortality have been brought closer to a solution. But that has not so far altered my considered opinion that "ductal adenocarcinoma of the pancreas is an incurable disease."¹ Incurable, that is, by the means at our disposal in this year 2002. It is true that the actual (not actuarial) 5-year survival of 118 patients who had their ductal adenocarcinoma of . . . [Full Text of this Article]

RELATED ARTICLES

This Month in Archives of Surgery
Arch Surg. 2002;137(7):769.
FULL TEXT  

Pancreatoduodenectomy for Pancreatic Adenocarcinoma: Triumph, Triumphalism, or Transition?
Edward L. Bradley III
Arch Surg. 2002;137(7):771-773.
EXTRACT | FULL TEXT